pSivida (NASDAQ:PSDV)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report issued on Tuesday. They presently have a $5.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 350.45% from the company’s current price.
Several other research firms also recently issued reports on PSDV. B. Riley set a $5.00 price target on pSivida and gave the stock a “buy” rating in a research note on Monday, December 4th. Laidlaw began coverage on shares of pSivida in a research note on Wednesday, November 8th. They issued a “buy” rating and a $5.00 target price for the company. Northland Securities reissued a “buy” rating and issued a $10.00 target price on shares of pSivida in a research note on Monday, December 11th. Finally, ValuEngine downgraded shares of pSivida from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $7.57.
Shares of pSivida (PSDV) traded up $0.05 during midday trading on Tuesday, hitting $1.11. 363,104 shares of the company’s stock traded hands, compared to its average volume of 315,125. The stock has a market cap of $50.24, a price-to-earnings ratio of -2.41 and a beta of 1.34. pSivida has a 52 week low of $1.02 and a 52 week high of $2.45.
An institutional investor recently bought a new position in pSivida stock. OxFORD Asset Management LLP bought a new position in shares of pSivida Corp. (NASDAQ:PSDV) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 69,004 shares of the company’s stock, valued at approximately $118,000. OxFORD Asset Management LLP owned 0.18% of pSivida as of its most recent filing with the SEC. Institutional investors own 9.70% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.com-unik.info/2018/01/11/psivida-psdv-earns-buy-rating-from-hc-wainwright.html.
pSivida Company Profile
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
Receive News & Ratings for pSivida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida and related companies with MarketBeat.com's FREE daily email newsletter.